Photo: SDI Productions/Getty Images
The National Comprehensive Cancer Network (NCCN) and OpenEvidence, an AI-enabled medical information platform for doctors, announced a licensing agreement to make NCCN’s evidence-based oncology guidelines available via OpenEvidence’s medical AI platform.
The licensing agreement will allow OpenEvidence to integrate content from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) and related content from JNCCN, the Journal of the National Comprehensive Cancer Network, into its clinician-facing AI platform.
Furthermore, the collaboration will allow healthcare professionals to enter NCCN’s evidence-based, "expert consensus-driven recommendations via natural-language search" and help clinicians locate information quicker.
The two companies said they aim to expand how guideline-based knowledge reaches clinicians by combining NCCN’s expertise in cancer care with OpenEvidence’s AI technology to help clinicians, streamline decision-making and achieve better results for patients.
THE LARGER TREND
In October, OpenEvidence announced a $200 million raise, bringing its valuation to $6 billion.
The investment came three months after the company secured $210 million in Series B funding, which boosted its valuation to $3.5 billion.
In February, OpenEvidence closed a Series A funding round, raising its valuation to $1 billion and bringing its total raise at the time to more than $100 million.
The funds were used to train its next-generation large language models and expand its team of scientists who work at the intersection of LLMs and medicine. It also used the investment to develop strategic content partnerships and work in conjunction with medical researchers to grow its library.
